Neurofibromatosis Type 1 (NF1) Tumor Spectrum
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Neuro-Oncology".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 1871
Special Issue Editors
Interests: NF1; peripheral nerve tumor; nervous system sarcoma; primary cell cultures; flow cytometry analysis
Interests: neurofibromatosis type 1; cancer biology; innate immune system; genome engineering technologies; drug susceptibility
Interests: pediatric cancers; liquid biopsy/cell free DNA; genomics and epigenetics; neurofibromatosis type 1; cancer predisposition syndromes; bioinformatics
Special Issue Information
Dear Colleagues,
This Special Issue is dedicated to the tumor spectrum associated with Neurofibromatosis Type 1 (NF1), the most common hereditary autosomal disorder, affecting approximately 1 in 2,500 individuals worldwide. The clinical manifestations of NF1 include café au lait spots (skin pigmentation), Lisch nodules, bone deformities, optic pathway gliomas, and low-grade gliomas. The hallmark of NF1 is neurofibroma, which are tumors associated with nerve endings in the skin (cutaneous neurofibromas) or within peripheral nerve trunks (plexiform neurofibromas). Notably, plexiform neurofibromas can transform into atypical neurofibromas and may progress to malignant peripheral nerve sheath tumors (MPNSTs), a leading cause of mortality for individuals with NF1. Despite recent advancements in molecular and cellular research, our understanding of the variability, complexity, and evolution of tumors in NF1 has remained incomplete since the disorder's discovery. The tumor microenvironment plays a critical role in the development of NF1 tumors, alongside genetic modifiers, and interaction networks. This Special Issue will explore the molecular and cellular mechanisms involved in the development of the NF1 tumor spectrum, including cutaneous, plexiform, and atypical neurofibromas, as well as MPNSTs and gliomas. We aim to address both basic and pre-clinical research to enhance our understanding of these complex tumors. Furthermore, we will highlight groundbreaking advancements in diagnostics, emphasizing the crucial role of genetic and molecular profiling in identifying at-risk patients and developing individualized treatment strategies. The issue will also feature discussions on the latest therapeutic innovations—such as targeted therapies, immunotherapies, and multimodal treatment regimens—aimed at improving outcomes for this vulnerable patient population. Additionally, this Special Issue will address important topics such as prognostic factors, survival rates, and the complexities involved in managing the various types of tumors related to NF1. By shedding light on the biology, clinical strategies, and cutting-edge treatments for these NF tumor spectra, this collection aims to enhance understanding and advance the quest for better care for those affected by NF1. We welcome original research articles and reviews.
Dr. Jay Pundavela
Dr. Kyle B. Williams
Dr. R. Taylor Sundby
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurofibromatosis type 1 (NF1)
- malignant tumors
- tumor spectrum
- molecular and cellular mechanisms
- malignant peripheral nerve sheath tumors (MPNSTs)
- targeted therapies
- immunotherapies
- prognostic factors
- survival outcomes
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
